Kahaly GJ, et al. - During this study, authors coveted a comparative evaluation of the efficacy and safety of add-on mycophenolate to methylprednisolone vs methylprednisolone alone in subjects with moderate-to-severe Graves' orbitopathy. Findings did not report any notable variation in the rate of response at 12 weeks or rate of relapse at 24 and 36 weeks. Nevertheless, post-hoc analysis displayed that addition of mycophenolate to treatment with methylprednisolone led to an improvement in the rate of response to therapy by 24 weeks in the study cohort.